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Our recent Communications Biology research article revealed the genomic drivers and
therapeutic vulnerabilities of sea turtle fibropapillomatosis tumors. Fibropapillomatosis is a
debilitating tumorous disease afflicting populations of green sea turtles globally. While a virus
is involved in the development of this disease, it is increasingly understood that the key
trigger is linked to anthropogenic disturbances of the environment. The specific environ-
mental co-trigger(s) has yet to be functionally confirmed. Here we outline the next steps
required to advance our understanding of this enigmatic disease, to enable us to more
effectively clinically combat it and to ultimately tackle its environmental co-trigger to halt and
hopefully reverse the spread of fibropapillomatosis.
As the risk of extinction of a species increases, so, too, does the effect of diseases on the
population of that species1,2. This can create a snowball effect whereby emerging pathogens
potentially accelerate the extinction of the species. Given the dire rate of habitat loss, biodiversity
decline and unparalleled human-induced species loss (on a par with previous mass extinction
events)3–7, it is imperative that we are increasingly vigilant in relation to endangered wildlife
disease outbreaks. Indeed, human activities might be contributing to oncogenic processes in wild
animal populations8,9. A host of tumorous diseases affecting wildlife populations are pathogen-
induced10,11, as are at least 15% of human cancers12,13. One such pathogen-induced tumorous
disease is sea turtle fibropapillomatosis, a virulent global epizootic (animal epidemic) leading to
tumors on turtles’ soft tissues and internal organs (Fig. 1). Individual turtles are often severely
afflicted by tens to hundreds of tumors which can lead to fatalities. The myriad other anthro-
pogenic threats that endangered sea turtle species already face (IUCN Red List, https://www.
iucnredlist.org/) means they can ill afford to also combat this disease. Our ability to manage,
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prevent and treat fibropapillomatosis is severely hampered by a
lack of knowledge of the disease’s triggers and the genomic events
driving tumor formation and growth.
Fibropapillomatosis afflicts all seven sea turtle species, of which
green sea turtles (Chelonia mydas) is the most severely afflic-
ted14–16. The number of stranded C. mydas exhibiting fibropa-
pillomatosis has dramatically increased in recent years, within
Florida and globally14,15,17. Fibropapillomatosis is ideally suited
to in-depth molecular and clinical study given the large numbers
of patients treated in rehabilitation facilities annually1,14,16,18.
Our application of cutting-edge genomic and precision medi-
cine approaches to fibropapillomatosis research has already
advanced sea turtle conservation medicine and provided novel
insights into viral-environmental oncogenic interactions applic-
able to human medicine1,14,18. Deep-sequencing-based approa-
ches are enabling dramatic advances1,19,20 beyond earlier
fibropapillomatosis gene expression research21. We revealed the
genomic drivers and therapeutic vulnerabilities of sea turtle
fibropapillomatosis in our recent Communications Biology arti-
cle14. The global importance of this disease16, combined with the
urgent need to modernize conservation medicine1, and the
potential insights this sea turtle tumor epidemic holds for human
environmental and pathogen-induced tumors1,14 has prompted
us to greatly expand the scope of our fibropapillomatosis
research. Here we discuss the advances required to better
understand and tackle this enigmatic conservation-relevant dis-
ease. Our ongoing research endeavors have the combined goals of
seeking to improve sea turtle conservation medicine and survival,
enhancing our fundamental understanding of this tumorous
disease, and advancing our comprehension of how detrimental
environmental-pathogen-host interactions can drive wildlife and
human tumorigenesis.
Tumor genomic & transcriptional profiling (host & virus) and
enhanced therapeutic target identification. Highlighting the
power of modern genomic and precision medicine techniques,
the transcriptomic profiling that formed the core of our recent
Communications Biology paper14 was performed using only
seven fibropapillomatosis tumor samples and three non-tumored
skin control samples (patient-matched). Despite this low sample
size we were able to gain important insight into the molecular
mechanisms driving fibropapillomatosis tumors, identify the
transcriptionally latent state of the fibropapilloma-associated
pathogen, Chelonid herpesvirus 5 (ChHV5) within established
tumors, and determine promising anti-fibropapillomatosis drug
treatments. However, many mysteries still remain in relation to
this disease. Therefore, we have greatly increased the number of
tumors (and control samples) transcriptomically profiled in order
to refine our drug target selection and answer a range of ques-
tions in relation to the environmental, host and viral drivers of
this disease. We are particularly interested in improving our
genomic understanding of early-stage tumors, post-surgical
regrowth tumors and internal tumors.
Understanding the genetic relationship between the numerous
tumors occurring on individual turtles will have implications for
the clinical treatment of the disease, as well as providing insight
into the initiating mechanisms of the tumors. We are actively
investigating whether these tumors are clonal (i.e. metastatically
spread) or if each tumor arises de novo (primary tumors) and has
unique mutational profile and impact on distinct tissue types. We
are also implementing detailed tumor (re)growth profiling to
more robustly assess growth dynamics and the effect of
therapeutic treatments18.
In terms of novel therapeutic approaches, because the vast
majority of patients are simultaneously afflicted by tens or more
tumors, we are prioritizing the identification of orally deliverable
compounds to achieve systemic responses. We are also
specifically seeking to identify therapeutic compounds for the
treatment of internal tumors, which are currently inoperable.
Internal tumors most commonly afflict the lungs, kidneys, heart,
gastrointestinal tract, and liver22. Currently no treatment exists
for turtles with visceral organ tumors, as the hard external
shell (plastron and carapace) hampers surgical access to
fibropapillomatosis-afflicted organs. Patients diagnosed with
internal tumors are instead humanely euthanized, often after
months of rehabilitation effort has already been expended.
In addition to determining host gene expression essential for
the maintenance and growth of fibropapillomatosis tumors it will
be crucial to further characterize the expression of ChHV5. We
are currently determining the abundance and differential
expression of ChHV5 viral transcripts across established tumors,
early-stage tumors, post-surgical regrowth tumors, and internal
tumors. Furthermore, we are employing unbiased deep-
sequencing approaches to compare viral transcript expression
levels with the overall level of ChHV5 DNA present within each
tumor. Previous approaches to investigate ChHV5 load have
primarily relied upon DNA-based PCR or qPCR of a small
a b
Fig. 1 Fibropapillomatosis-afflicted green sea turtles (C. mydas). Anterior (a) and posterior (b) view of fibropapillomatosis tumors on juvenile green sea
turtles prior to tumor removal surgery at the University of Florida’s Whitney Laboratory Sea Turtle Hospital. Right image used under creative commons
license, CC BY-ND (https://theconversation.com/could-human-cancer-treatments-be-the-key-to-saving-sea-turtles-from-a-disfiguring-tumor-disease-
98140)
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number of ChHV5 assays or targeted ChHV5 genome sequen-
cing (e.g. enrichment of ChHV5 DNA by long-range PCR
amplification)23–25.
Together this research promises to shed further light on the
viral and host molecular mechanisms responsible for the
initiation, maintenance and regrowth of fibropapillomatosis
tumors, enabling the design of rational treatment strategies.
Prognostic biomarkers and viral shedding. We are exploring
the potential of prognostic and diagnostic biomarkers to improve
the clinical care of fibropapillomatosis-afflicted sea turtles. Cur-
rently, x-ray, endoscopy, magnetic resonance imaging (MRI), or
computed tomography (CAT) scans are required to diagnose
internal tumors. To overcome their limitations in hard-shelled
patients, including difficulty in detecting early-stage tumors, we
are researching the diagnostic and prognostic value of qPCR-
based blood-plasma biomarkers. We are investigating putative
biomarkers for both the detection of internal tumors, and bio-
markers capable of predicting ultimate rehabilitation outcome of
individual turtles. Circulating tumor DNA in blood is a well-
established source material for blood-based biomarkers for can-
cer detection, and is increasingly utilized in human oncology26–
28.
We are also utilizing pioneering environmental DNA (eDNA)
screening techniques to quantify the level of ChHV5 viral
shedding in fibropapillomatosis-afflicted sea turtles. eDNA is an
ultra-modern approach, whereby free DNA is isolated directly
from an environmental sample (e.g. cellular material from water)
and subsequently detected by molecular approaches29–31 (e.g.
deep sequencing or qPCR). By tracking the level of virus shed
into the environment by each patient, we will better understand
disease transmission dynamics. Furthermore, by correlating viral
shedding to individuals throughout the various stages of the
rehabilitation process, and individuals with varying tumor
burdens and tumor aggressiveness18 we can begin to quantify
whether there are certain times/states which promote enhanced
viral shedding. Such profiling can also help inform clinical
management (e.g. isolation of high rate viral shedders), and
potentially improve our understanding of how this disease
spreads throughout the marine environment.
Dynamics of environmental fibropapillomatosis disease ori-
gins. While ChHV5 is likely a key driver of fibropapillomatosis,
additional environmental co-triggers are required to drive
fibropapillomatosis tumor formation in a laboratory setting32 and
in wild populations. A number of potential environmental co-
triggers have been investigated, some of which correlate strongly
with the disease incidence. However, no factor has yet been
causatively proven to drive fibropapillomatosis tumor
development14,16.
While there are a number of putative environmental triggers
that warrant further investigation, the correlation between
elevated ultraviolet (UV) radiation levels and disease incidence,
as well as the shared molecular drivers of fibropapillomatosis and
human basal cell carcinoma14 suggest a possible role of UV
radiation as an environmental co-trigger of fibropapillomatosis.
This includes the differential regulation of Wnt and Metallopro-
tease signaling14 in fibropapillomatosis. These pathways are
known to be regulated by UV exposure in human skin cells and
canine cornea33,34. UV exposure has been linked to systemic
immunosuppression35,36, which also occurs in turtles with
fibropapillomatosis, although it is not yet determined whether
this is a cause or a consequence of the disease16. Elevated UV
exposure therefore holds the potential to induce immunosup-
pression in turtle skin, possibly enabling the rampant prolifera-
tion of ChHV5 and the crossing of an oncogenic threshold.
UV exposure is also a known tumorigenic mutagen37.
Fibropapillomatosis tumors primarily occur on external regions,
suggesting UV light may act as a direct mutagen contributing to
oncogenesis, like with other human and wildlife skin cancers. UV
exposure induces signature mutations in genes such as p53
(Tp53) and Patched (Ptch), two tumor suppressor genes
responsible for human non-melanoma skin cancer37. Sunlight
also acts as a tumor promoter by favoring clonal expansion of
such mutated cells37. Expression of both Ptch genes are highly
suppressed in fibropapillomatosis tumors14 (Fig. 2). Mutational
analysis of tumor genomes is now required to confirm whether
this is due to UV-induced mutations. We have begun to
investigate the presence of mutations within fibropapillomatosis
tumors, focusing primarily on UV-induced signatures. This
approach38–40 will also identify any other mutation-inducing
exogenous exposures responsible for driving fibropapillomatosis
tumorigenesis.
Juvenile C. mydas, the life-stage afflicted by fibropapillomatosis,
reside in shallower UV-exposed tropical and sub-tropical inshore
waters, while the predominantly tumor free post-hatchlings, sub-
adults, and adults dwell in the open water16. A role of UV in the
disease’s etiology would help to explain the unusual dynamics of its
geographic spread. Fibropapillomatosis took over 80 years to spread
from the Florida Keys (first recorded site of FP incidence





































Fig. 2 Downregulation of Patched (Ptch) tumor suppressor genes in fibropapillomatosis tumors, as revealed by RNA-seq, adapted from Duffy et al.14
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neighboring juvenile green turtle populations running the length of
the entire seaboard. Conversely, in a shorter time period the disease
spread to distant C. mydas populations circum-globally, throughout
equatorial and sub-equatorial zones15. UV levels reaching the
Earth’s surface have increased in recent times both locally in
Florida14 and globally43, potentially driving the spread of the
disease away from the equator and increasing incidence in some
longer-affected areas.
UV might also indirectly contribute to tumourigenesis by
converting inshore chemicals into more potentent oncogenic
forms. UV light is known to degrade organic compounds in
natural waters (photolysis). Complex organic (often poly-
unsaturated/aromatic) molecules can be broken down into
smaller, more reactive compounds that can then react with each
other forming different, potentially harmful compounds44,45.
While this process is globally ubiquitous, matching fibropapillo-
matosis incidence, it is most prominent in tropical and
subtropical latitudes where sunlight is most intense and in areas
where organic compound concentrations are highest (nearshore
and estuarine waters). Therefore, this offers another potential
mechanism through which UV could be indirectly contributing
to fibropapillomatosis initiation.
Whether fibropapillomatosis tumourigenesis is triggered by
UV directly (induction of genomic mutations) or indirectly (UV-
induced immunosuppression or UV-induced conversion of
inshore chemicals), with the increases in UV exposure occurring
globally it is likely that mechanistic findings will be highly
relevant not only for sea turtle fibropapillomatosis but also other
human and wildlife oncogenic diseases.
Human and wildlife precision medicine: mutually beneficial
crosspollination. Fibropapillomatosis provides an ideal oppor-
tunity to study pathogen and environmentally co-induced
tumors. This will improve our ability to combat not only this
sea turtle disease epizootic but also the ever-increasing number of
wildlife and human cancers discovered to be pathogen-induced
(over 15% of human cancers13) or exacerbated by pathogens46,47.
The key role of environmental co-triggers further complicates our
understanding of pathogen-induced cancers. In humans, study-
ing the initiating events that can go on to produce later cancers is
difficult. Once assumed to be an issue for vulnerable cohorts (e.g.
Kaposi sarcoma-associated herpesvirus drives tumor formation
in immunocompromised patients)12, it is now understood that
temporally distant viral events can sow the seeds of later cancers
(e.g. human papilloma virus [HPV] infection can ultimately
result in cervical and throat cancers48). HPV is also clinically
associated with human non-melanoma skin cancer, including
basal cell carcinoma48–50 which is the cancer type that tran-
scriptomically most closely resembles chelonid fibropapilloma-
tosis14. Furthermore, UV radiation and HPV infection are linked
to human non-melanoma skin cancer, with UV-induced immu-
nosuppression being a likely driving mechanism35,51. We
urgently need tractable natural models of virally induced tumors
to fully understand the role of pathogens in driving tumor for-
mation and to determine environmental co-initiation mechan-
isms52. Sea turtles have a similar life-span to humans and have
normally robust anti-cancer defenses, providing a more faithful
comparative model of humans than common short-lived cancer
models, such as rodents and zebrafish1. Fibropapillomatosis
offers an intriguing new glimpse into a potentially devastating
disease mechanism, revealing that an environmental co-factor is
potent enough to enable a normally benign virus to cause disease
of epidemic (epizootic) proportions in otherwise healthy juvenile
populations. Intensive study of chelonid fibropapillomatosis will
enable us to directly address the crucial question of how an
environmental trigger is capable of conferring such potent
oncogenicity on a clinically benign virus, an issue that potentially
holds immense importance for our understanding of human and
wildlife pathogen-induced tumors.
Future outlook. Interesting work is emerging regarding green
turtle cell culture and the enigmatic ChHV5 virus23,53,54.
Importantly, the breakthrough enabling the long sought-after
ability to culture the virus in the lab means that Koch’s postulates
(four criteria required to identify the causative agent of an
infectious disease) can hopefully be fully assessed in the near
future53. If Koch’s postulates are fulfilled, ChHV5 can finally be
comprehensively claimed as the primary pathogenic agent driving
tumor formation, albeit possibly still requiring environmental co-
trigger(s) to unleash sufficient viral loads. Alternatively, if not
fulfilled this will demonstrate that ChHV5 inoculation/exposure
alone truly is not sufficient to drive this disease and that another
trigger(s)/co-trigger(s) is essential to initiate fibropapillomatosis
tumor growth. While it is possible that an alternative pathogen
might be identified, the correlation of ChHV5 viral load to tumors
and the lack of other pathogens in significant abundance within
the tumors16 makes this less likely. The lack of a specific tumor
associated virulent ChHV5 strain and the presence of ChHV5 in
tumor-free populations16 demonstrate that the limiting factor in
developing fibropapillomatosis is not just exposure to ChHV5 but
also exposure to the elusive inshore environmental co-trigger(s).
Advances in cell biology, environmental oncogenic trigger
detection and assessment, and genomic medicine mean that now
more than ever we are within sight of revealing the longstanding
mysteries of the fibropapillomatosis disease epizootic. For our
part, we will continue to pioneer advanced genomic and precision
wildlife medicine approaches aiming to better understand, treat
and ultimately prevent the burden of fibropapillomatosis on sea
turtle populations.
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